echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA launches drug production reporting portal and releases relevant guidance

    FDA launches drug production reporting portal and releases relevant guidance

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The US FDA launched a new NextGen portal on October 29 to report production data of pharmaceuticals and biological products under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), and subsequently issued two guidelines Help registrants comply with regulations and reporting requirements
    .

    The portal and related guidelines were released after the FDA delayed the collection of drug production data for more than a year in August 2020
    .


    At that time, the FDA stated that the portal could not be ready by September 23, 2020, as required by the bill


    Section 3112 of the CARES Act establishes new reporting requirements for pharmaceutical manufacturers to improve response to drug shortages, including expanding the reporting requirements for shortages of life-saving drugs to include “critical to public health in a public health emergency "Drugs, and the raw materials for these drugs
    .


    "

    The bill also requires pharmaceutical manufacturers to report production data to the FDA under Section 3112(e), including “the production volume of each drug produced, prepared, cultivated, formulated, or processed for commercial distribution
    .


    ” The bill also allows the FDA to request electronic format Submit this information and give the Minister of Health discretion to waive some or all of the production data reporting requirements for biological products


    The FDA stated that “the reported data will increase the FDA’s visibility into the drug supply chain and will help the FDA identify, prevent and alleviate drug shortages
    .


    ” The FDA pointed out that the 2020 calendar year report should be submitted by February 15, 2022.


    The two guidelines provide registrants with recommendations on reporting requirements and the process of submitting reports, as well as the technical consistency details of the submission of reports and the data elements that should be included
    .


    The FDA proposes to exempt two types of products from the reporting requirements: blood and blood components used for blood transfusion, and each batch of cell and gene therapy products used to treat a single patient


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.